Data Analysis

1. Capomulin appeared to decrease the tumor size over the span of 45 days, while Infubinoal, Ketapril, and Placebo had the tumor size increase over the same span.
2. Over the span of 45 days, Ketapril and Placebo looked to have the same meatastatic spread. The placebo was clearly better over the first 40 days, but the Ketapril made a big jump over the final five days of testing. It would be interesting to see if the Ketapril would continue to make a large jump over the next 15-20 days.
3. The Capomulin had the best survival rate over the 45-day trial with a rate of 85%. The other three drugs tested had survival rates lower than 50%.
4. Capomulin would be the drug I would suggest moving forward when it comes to treating tumors.